No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome.
Lundin
Jeanette
J
Kennedy
Ben
B
Dearden
Claire
C
Dyer
Martin J S
MJ
Osterborg
Anders
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy* / Q000276:immunology; D012189:Retrospective Studies; D012751:Sezary Syndrome / Q000188:drug therapy* / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab